Effects of chronic L-theanine administration in patients with major depressive disorder: an open-label study

Shinsuke Hidese1,2, Miho Ota1, Chisato Wakabayashi1, Takamasa Noda3, Hayato Ozawa4, Tsutomu Okubo4, Hiroshi Kunugi1,2

1Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; 2Department of NCNP Brain Physiology and Pathology, Division of Cognitive and Behavioral Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan; 3Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; and 4Department of Research and Development, Nutrition Division, Taiyo Kagaku Co. Ltd, Mie, Japan

Keywords: anxiety; cognitive function; depression; L-theanine; sleep

Dr. Hiroshi Kunugi, Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

Objective: L-theanine, an amino acid uniquely contained in green tea (Camellia sinensis), has been suggested to have various psychotropic effects. This study aimed to examine whether L-theanine is effective for patients with major depressive disorder (MDD) in an open-label clinical trial.

Methods: Subjects were 20 patients with MDD (four males; mean age: 41.0 ± 14.1 years, 16 females; 42.9 ± 12.0 years). L-theanine (250 mg/day) was added to the current medication of each participant for 8 weeks. Symptoms and cognitive functions were assessed at baseline, 4, and 8 weeks after L-theanine administration by the 21-item version of the Hamilton Depression Rating Scale (HAM-D-21), State-Trait Anxiety Inventory (STAI), Pittsburgh Sleep Quality Index (PSQI), Stroop test, and Brief Assessment of Cognition in Schizophrenia (BACS).

Results: HAMD-21 score was reduced after L-theanine administration (p = 0.007). This reduction was observed in unremitted patients (HAM-D-21 > 7; p = 0.004) at baseline. Anxiety-trait scores decreased after L-theanine administration (p = 0.012) in the STAI test. PSQI scores also decreased after L-theanine administration (p = 0.030) in the unremitted patients at baseline. Regarding cognitive functions, response latency (p = 0.001) and error rate (p = 0.036) decreased in the Stroop test, and verbal memory (p = 0.005) and executive function (p = 0.016) were enhanced in the BACS test after L-theanine administration.

Conclusion: Our study suggests that chronic (8-week) L-theanine administration is safe and has multiple beneficial effects on depressive symptoms, anxiety, sleep disturbance and cognitive impairments in patients with MDD. However, since this is an open-label study, placebo-controlled studies are required to consolidate the effects.

Significant outcomes

- Depressive symptoms, anxiety, and sleep disturbance were improved after L-theanine administration in patients with major depressive disorder (MDD).
- Cognitive functions were enhanced after L-theanine administration in patients with MDD.
- High tolerability of L-theanine was suggested.

Limitations

- This study was an open-label trial.
- The majority of the subjects was affected by relatively mild forms of MDD.
- The number of the subjects was small.
**L-theanine and depression**

**Introduction**

MDD is a serious mental illness presenting with depressed mood, anxiety, sleep disturbance, various somatic symptoms, and cognitive impairments (1,2). Although many antidepressants acting on synaptic monoamine levels have been used as the first-line drug treatment for MDD, they are not effective in a substantial proportion of patients (3). In addition, they can often elicit intolerable side effects in patients. This justifies the development of new treatment strategies in terms of efficacy and tolerability for patients suffering from MDD (4). Several natural compounds (e.g. St. John’s wort, omega-3 fatty acids, and S-adenosyl-l-methionine) have been reported to be effective for MDD, whereas having fewer side effects and relatively low placebo response rates than antidepressants (5,6).

L-theanine (L-γ-glutamylethylamide) is a non-proteinous amino acid, which is uniquely contained in green tea (Camellia sinensis). L-theanine crosses the blood–brain barrier, and is transported into the brain in a dose-dependent manner (7). The chemical structure of L-theanine resembles that of L-glutamate and competes with it on glutamate receptors (8). In experiments on rats, stress-induced suppression of recognition memory was rescued by L-theanine administration, which recovered the attenuation of in vitro hippocampal CA1 long-term potentiation (LTP) after stress exposure (9). Recognition memory was also enhanced in the L-theanine-administered rats, showing increased population spike amplitude in the induction of in vivo hippocampal dentate gyrus LTP (10). It has been shown that L-theanine has various psychotropic effects (11). In experiments on mice, depression-like behaviour and cognitive dysfunction in a confront-housing condition, a model of chronic psychosocial stress, were suppressed in the L-theanine intake group (12). We also reported the antidepressant-like effect of L-theanine together with the agonistic action on N-methyl-D-aspartate receptors (13). It has also been shown that anxiety-associated behaviours decrease (14), and that chronic stress-induced cognitive impairments improve (15) in the L-theanine-administered mice.

In healthy humans, L-theanine was effective in reducing state anxiety scores, as well as in decreasing sympathetic nerve responses following acute stress task (16). In electroencephalogram studies, L-theanine affected both resting state (17) and attention task-related (18,19) α-wave activity which influences prefrontal cortical function, contributing to cognitive processes associated with attention and memory (20). Error rates in the attention task decreased in healthy participants (21), and cognitive functions, including attention and memory, also improved in subjects exhibiting mild cognitive impairment (22) in the L-theanine-administered group. Further, L-theanine showed augmentative effects on antipsychotic therapy in patients with schizophrenia and schizoaffective disorder, improving positive, activation, dysphoric mood, and anxiety symptoms (23). We have also reported similar symptom-reducing effects of L-theanine in patients with schizophrenia (24).

**Aims of the study**

Although L-theanine has been shown to have various psychotropic effects, there has been no clinical study performed to show whether this compound affects symptoms and cognitive functions in patients with MDD. The aim of this study was to examine the psychotropic effects of L-theanine in patients with MDD.

**Material and methods**

**Subjects**

Subjects (mean age: 42.6 ± 12.1 years, four males and 16 females) were 20 patients with the diagnosis of MDD according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (25). Each diagnosis was based on information obtained by the Mini-International Neuropsychiatric Interview (26), and additional unstructured interviews, and medical records where available. We included some remitted patients with MDD as well as unremitted patients at baseline in order to elucidate the possible effects of L-theanine on mild forms of the illness. Participants were excluded if they had prior medical histories of central nervous system disease, severe head injury, substance abuse, or mental retardation. All patients were recruited from the outpatients of the National Center of Neurology and Psychiatry Hospital (n = 6) or from the local community through prepared advertisements (n = 14). After describing the study, written informed consent was obtained from every subject. Thereafter, patient anonymity has been preserved. Before starting the study, we registered the protocol at the university hospital medical information network – clinical trials registry and complied with it accordingly (UMIN000014653).

**L-theanine administration**

After the initial psychiatric assessments, L-theanine tablets (250 mg/day) (Suntheanine, Taiyo Kagaku Co. Ltd, Japan) were orally administered before sleep for 8 weeks. This dose was chosen because it was effective in our prior study (24). Psychiatric
symptoms were assessed at baseline, 4 and 8 weeks after l-theanine administration. In total, 12 patients (60%) were treated with antidepressant medication at baseline and this medication was unchanged during our intervention period. Daily doses of antidepressants were converted to imipramine-equivalent doses using a published Japanese guideline (27). The mean imipramine-equivalent dose was calculated in the total subjects (n = 20). Participants were instructed not to alter their usual intakes of green tea during the intervention period.

Clinical assessments

To evaluate depressive symptoms, anxiety, and sleep state, the 21-item version of the GRID Hamilton Depression Rating Scale (HAMD-21) (28,29), State-Trait Anxiety Inventory (STAI) (30), and Pittsburgh Sleep Quality Index (PSQI) (31) were used. Adverse events were assessed using the Udvalg for Klinicke Undersøgelser (UKU) side effect rating scale (32). Cognitive functions were measured by the Stroop test (33) and the Brief Assessment of Cognition in Schizophrenia (BACS) (34). The Stroop test was conducted on a computer using two types (control and experimental condition) of PowerPoint files composed of four (red, blue, yellow, and black) coloured words (35). After the participants practiced by the control condition in which colour and word were consistent, response latency (ms) and error rate (%) were evaluated in the experimental condition in which colour and word were inconsistent. Two versions (A and B) of BACS were used to exclude any learning effects.

Laboratory tests

Non-fasting blood samples were obtained before clinical assessments. Serum samples were prepared by centrifuging bloods for 10 min at 3,000 rotations/min. Plasma samples were prepared to measure haemoglobin A1c. The samples were evaluated at baseline, 4 and 8 weeks after l-theanine administration at SRL Co. Ltd, Japan to check general physical states and monitor side effects. Serum l-theanine concentrations were measured by a high-performance liquid chromatography system based on blood concentrations were measured by a high-performance liquid chromatography system based on the AccQ-Tag method as described in the literature (36) using commercially available reagents and equipment (Waters Corp., Tokyo, Japan).

Statistics

Differences in clinical assessments and laboratory data between baseline and 8 weeks after l-theanine administration were analysed by the Wilcoxon’s signed-rank test. Effect sizes were calculated using r values. All statistical tests were two-tailed and p < 0.05 indicated statistical significance. Statistical analyses were performed using the Statistical Package for the Social Sciences version 22.0 (IBM Corp., Tokyo, Japan).

Results

The clinical characteristics of the subjects are summarised in Table 1. All participants completed the entire 8-week study, suggesting high tolerability of l-theanine. Time courses of symptom scores are shown in Table 2. Six HAMD-21 subscale scores were calculated as described in Seretti et al. (37). There was a significant decrease in HAMD-21 total scores (p = 0.007, r = −0.61), and a significant reduction in four subscale scores (core, psychic anxiety, somatic anxiety, and delusion) and a tendency of reduction in sleep subscale scores in the total patients (n = 20). When the patients were divided into unremitted patients (HAMD-21 > 7; n = 13) at baseline and the remaining remitted patients (n = 7) according to Riedel et al. (38), the former showed a significant decrease (p = 0.004, r = −0.79), whereas the latter did not (p = 0.35, r = −0.36) (Fig. 1). Among the unremitted patients at baseline, six (46.2%) were responders (50% or more reduction of HAMD-21 score) and six (46.2%) became remitters at 8 weeks. Among the remitted patients at baseline, there were only two (28.6%) responders. We did not detect any significant association of clinical variables (age, sex, height, weight, body mass index, education, onset of illness, single/recurrent episode, imipramine-equivalent dose, or smoking) with response to l-theanine (data not shown).

STAI consisted of anxiety-state and anxiety-trait indices. We found a tendency of reduction in anxiety-state (p = 0.058, r = −0.43), and a significant reduction in anxiety-trait (p = 0.012, r = −0.56)
**Table 2. Time courses of symptom scores after L-theanine administration**

<table>
<thead>
<tr>
<th></th>
<th>Baseline (mean ± SD)</th>
<th>4 weeks (mean ± SD)</th>
<th>8 weeks (mean ± SD)</th>
<th>Wilcoxon’s signed-rank test</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAMD-21</td>
<td>12.5 ± 8.0</td>
<td>8.5 ± 6.3</td>
<td>8.8 ± 7.8</td>
<td>W = 19.5, **p = 0.007, r = −0.61</td>
</tr>
<tr>
<td>Non-remitters*</td>
<td>16.2 ± 7.6</td>
<td>10.6 ± 6.7</td>
<td>10.7 ± 6.1</td>
<td>W = 1.0, **p = 0.004, r = −0.79</td>
</tr>
<tr>
<td>Remitters†</td>
<td>5.7 ± 1.4</td>
<td>4.4 ± 2.5</td>
<td>5.3 ± 6.4</td>
<td>W = 6.0, p = 0.35, r = −0.36</td>
</tr>
<tr>
<td>Core</td>
<td>6.9 ± 3.4</td>
<td>4.5 ± 3.4</td>
<td>5.1 ± 4.4</td>
<td>W = 31.5, *p = 0.018, r = −0.53</td>
</tr>
<tr>
<td>Sleep</td>
<td>1.0 ± 1.2</td>
<td>0.7 ± 1.1</td>
<td>0.6 ± 0.8</td>
<td>W = 8.0, p = 0.070, r = −0.41</td>
</tr>
<tr>
<td>Activity</td>
<td>1.7 ± 1.3</td>
<td>0.8 ± 1.1</td>
<td>1.3 ± 1.5</td>
<td>W = 29.0, p = 0.12, r = −0.42</td>
</tr>
<tr>
<td>Psychic anxiety</td>
<td>1.7 ± 1.1</td>
<td>1.0 ± 0.8</td>
<td>1.1 ± 0.9</td>
<td>W = 11.0, *p = 0.012, r = −0.57</td>
</tr>
<tr>
<td>Somatic anxiety</td>
<td>2.5 ± 2.1</td>
<td>1.8 ± 1.4</td>
<td>1.7 ± 1.7</td>
<td>W = 8.0, *p = 0.023, r = −0.51</td>
</tr>
<tr>
<td>Delusion</td>
<td>1.9 ± 1.6</td>
<td>1.2 ± 1.5</td>
<td>1.0 ± 1.3</td>
<td>W = 17.1, *p = 0.024, r = −0.51</td>
</tr>
<tr>
<td>STAI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxiety-state</td>
<td>52.9 ± 11.5</td>
<td>51.5 ± 11.2</td>
<td>49.5 ± 11.6</td>
<td>W = 48.0, p = 0.058, r = −0.43</td>
</tr>
<tr>
<td>Non-remitters*</td>
<td>56.6 ± 11.5</td>
<td>54.1 ± 12.4</td>
<td>52.5 ± 12.2</td>
<td>W = 25.5, p = 0.16, r = −0.39</td>
</tr>
<tr>
<td>Remitters†</td>
<td>45.9 ± 8.0</td>
<td>46.6 ± 7.0</td>
<td>43.9 ± 8.5</td>
<td>W = 2.0, p = 0.072, r = −0.68</td>
</tr>
<tr>
<td>Anxiety-trait</td>
<td>58.2 ± 13.0</td>
<td>54.3 ± 11.8</td>
<td>53.5 ± 12.8</td>
<td>W = 33.0, *p = 0.012, r = −0.56</td>
</tr>
<tr>
<td>Non-remitters*</td>
<td>61.8 ± 13.6</td>
<td>57.1 ± 12.0</td>
<td>56.0 ± 13.6</td>
<td>W = 18.0, p = 0.054, r = −0.53</td>
</tr>
<tr>
<td>Remitters†</td>
<td>51.6 ± 9.1</td>
<td>49.1 ± 10.5</td>
<td>48.7 ± 10.4</td>
<td>W = 1.0, *p = 0.046, r = −0.76</td>
</tr>
<tr>
<td>PSQI</td>
<td>9.6 ± 3.7</td>
<td>8.8 ± 3.2</td>
<td>9.1 ± 2.6</td>
<td>W = 41.5, p = 0.16, r = −0.31</td>
</tr>
<tr>
<td>Non-remitters*</td>
<td>10.6 ± 3.8</td>
<td>9.5 ± 3.6</td>
<td>9.5 ± 2.9</td>
<td>W = 6.5, *p = 0.030, r = −0.60</td>
</tr>
<tr>
<td>Remitters†</td>
<td>7.6 ± 2.8</td>
<td>7.4 ± 1.8</td>
<td>8.1 ± 1.8</td>
<td>W = 12.5, p = 0.67, r = 0.16</td>
</tr>
</tbody>
</table>

HAMD-21, 21-item version of the Hamilton Depression Rating Scale; PSQI, Pittsburgh Sleep Quality Index; STAI, State-Trait Anxiety Inventory; W, Wilcoxon’s signed-rank test statistic.

* HAMD-21 > 7 (n = 13).
† HAMD-21 ≤ 7 (n = 7).
*p < 0.05, **p < 0.01.

**Fig. 1. Twenty-one-item version of the Hamilton Depression Rating Scale (HAMD-21) score change after L-theanine administration.** There was a significant reduction of HAMD-21 scores in unremitted patients (n = 13), whereas such a significant change was not observed in remitted patients (n = 7, grey coloured). n.s., Not significant. **p < 0.01.

after L-theanine administration in the total patients. PSQI scores were significantly reduced after L-theanine administration in the patients who were unremitted at baseline (p = 0.030, r = −0.60). We found no notable adverse events in the UK side effect rating scale (4 weeks: 0.2 ± 0.5, 8 weeks: 0.3 ± 0.6). One patient reported slight sleepiness, two patients reported increased duration of sleep of up to 2 h longer than usual, and two patients reported slightly increased dream activity.

Time courses of cognitive function scores are shown in Table 3. In the Stroop test, response latency was significantly shortened after L-theanine administration (p = 0.001, r = −0.72). There was also a significant decrease in error rate in the Stroop test (p = 0.036, r = −0.47). Among seven indices of BACS, verbal memory score (p = 0.005, r = 0.63) and executive function score (p = 0.016, r = 0.54) were significantly enhanced after L-theanine administration.

Changes in laboratory data are shown in Table 4. Except for a significant decrease of high-density lipoprotein (HDL) cholesterol (p = 0.011, r = −0.57), general metrics such as liver function, renal function, and glucose metabolism were not significantly altered after L-theanine administration. As expected, L-theanine blood concentration significantly increased after administration (p = 0.005, r = 0.64).

**Discussion**

We examined the possible effects of L-theanine in an open-label clinical trial. We found that psychiatric symptoms and cognitive functions of patients with MDD were improved after L-theanine administration. HAMD-21 scores, an objective index of depression, were reduced in unremitted patients at baseline;
Table 3. Time courses of cognitive function scores after l-theanine administration

<table>
<thead>
<tr>
<th>Category</th>
<th>Baseline (mean ± SD)</th>
<th>4 weeks (mean ± SD)</th>
<th>8 weeks (mean ± SD)</th>
<th>Wilcoxon's signed-rank test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroop test</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Response latency (ms)</td>
<td>1216 ± 324</td>
<td>1130 ± 286</td>
<td>1080 ± 307</td>
<td>W = 18.5, **p = 0.001, r = −0.72</td>
</tr>
<tr>
<td>Error rate (%)</td>
<td>2.4 ± 2.3</td>
<td>1.5 ± 1.5</td>
<td>1.2 ± 1.4</td>
<td>W = 13.0, *p = 0.036, r = −0.47</td>
</tr>
<tr>
<td>BACS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verbal memory</td>
<td>48.1 ± 9.7</td>
<td>48.7 ± 10.5</td>
<td>53.2 ± 8.0</td>
<td>W = 164.5, **p = 0.005, r = 0.63</td>
</tr>
<tr>
<td>Working memory</td>
<td>22.0 ± 3.2</td>
<td>21.6 ± 3.1</td>
<td>21.5 ± 3.3</td>
<td>W = 66.0, p = 0.61, r = −0.11</td>
</tr>
<tr>
<td>Motor speed</td>
<td>79.0 ± 15.3</td>
<td>83.2 ± 14.6</td>
<td>81.8 ± 17.4</td>
<td>W = 121.0, p = 0.29, r = 0.24</td>
</tr>
<tr>
<td>Category fluency</td>
<td>22.9 ± 6.6</td>
<td>24.9 ± 7.6</td>
<td>24.6 ± 6.1</td>
<td>W = 101.5, p = 0.24, r = 0.27</td>
</tr>
<tr>
<td>Letter fluency</td>
<td>27.8 ± 8.7</td>
<td>28.4 ± 8.7</td>
<td>29.8 ± 10.1</td>
<td>W = 143.5, p = 0.15, r = 0.32</td>
</tr>
<tr>
<td>Attention</td>
<td>64.0 ± 13.5</td>
<td>63.2 ± 12.4</td>
<td>66.1 ± 14.6</td>
<td>W = 121.5, p = 0.12, r = 0.35</td>
</tr>
<tr>
<td>Executive function</td>
<td>17.5 ± 2.4</td>
<td>17.2 ± 2.6</td>
<td>19.0 ± 1.7</td>
<td>W = 102.0, *p = 0.016, r = 0.54</td>
</tr>
</tbody>
</table>

BACS, Brief Assessment of Cognition in Schizophrenia; W, Wilcoxon’s signed-rank test statistic. *p < 0.05, **p < 0.01.

Table 4. Changes in laboratory data after l-theanine administration

<table>
<thead>
<tr>
<th>Category</th>
<th>Baseline (mean ± SD)</th>
<th>4 weeks (mean ± SD)</th>
<th>8 weeks (mean ± SD)</th>
<th>Wilcoxon’s signed-rank test</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST (IU/l)</td>
<td>23.8 ± 14.0</td>
<td>21.5 ± 9.7</td>
<td>23.3 ± 11.9</td>
<td>W = 59.5, p = 0.42, r = −0.18</td>
</tr>
<tr>
<td>ALT (IU/l)</td>
<td>22.9 ± 19.7</td>
<td>22.3 ± 18.6</td>
<td>21.5 ± 16.9</td>
<td>W = 60.0, p = 0.81, r = −0.05</td>
</tr>
<tr>
<td>y-GTP (IU/l)</td>
<td>30.0 ± 30.0</td>
<td>27.8 ± 31.2</td>
<td>32.0 ± 35.9</td>
<td>W = 108.5, p = 0.36, r = 0.21</td>
</tr>
<tr>
<td>CRE (mg/dl)</td>
<td>0.7 ± 0.1</td>
<td>0.7 ± 0.1</td>
<td>0.7 ± 0.1</td>
<td>W = 70.0, p = 0.50, r = −0.15</td>
</tr>
<tr>
<td>BUN (mg/dl)</td>
<td>12.6 ± 3.7</td>
<td>12.4 ± 3.8</td>
<td>11.9 ± 3.3</td>
<td>W = 79.0, p = 0.33, r = −0.22</td>
</tr>
<tr>
<td>T-CHO (mg/dl)</td>
<td>197.3 ± 27.5</td>
<td>192.2 ± 32.1</td>
<td>192.0 ± 30.5</td>
<td>W = 77.0, p = 0.30, r = −0.23</td>
</tr>
<tr>
<td>HDL-CHO (mg/dl)</td>
<td>62.0 ± 16.5</td>
<td>60.0 ± 15.2</td>
<td>57.6 ± 13.7</td>
<td>W = 27.0, *p = 0.011, r = −0.57</td>
</tr>
<tr>
<td>LDL-CHO (mg/dl)</td>
<td>105.0 ± 28.0</td>
<td>107.3 ± 24.6</td>
<td>107.1 ± 24.6</td>
<td>W = 86.0, p = 0.48, r = −0.16</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>126.6 ± 96.1</td>
<td>127.9 ± 96.6</td>
<td>135.3 ± 93.0</td>
<td>W = 141.5, p = 0.17, r = 0.31</td>
</tr>
<tr>
<td>Hb A1c (%)</td>
<td>5.8 ± 1.3</td>
<td>5.7 ± 1.2</td>
<td>5.8 ± 1.4</td>
<td>W = 107.0, p = 0.63, r = 0.11</td>
</tr>
</tbody>
</table>

ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; CRE, creatinin; GTP, glutamyltranspeptidase; Hb, haemoglobin; HDL-CHO, high-density lipoprotein cholesterol; LDL-CHO, low-density lipoprotein cholesterol; T-CHO, total cholesterol; TG, triglyceride; W, Wilcoxon’s signed-rank test statistic. *p < 0.05.

although the score-reducing effect was not observed any more in patients who were already remitted at baseline. Among the HAMD-21 subscales, core, psychotic anxiety, somatic anxiety, and delusion scores were reduced. The scores in STAI and PSQI metrics were also reduced. Response latency and error rate decreased in the Stroop test and verbal memory and executive function increased in the BACS. Furthermore, there were no dropout subjects and no serious adverse events in either UKU side effect rating scale or laboratory data. To our knowledge, we showed, for the first time, reduced symptoms and enhanced cognitive functions in patients with MDD after l-theanine administration, suggesting that it possesses multiple favourable psychotropic effects.

Depressive symptoms were significantly reduced after l-theanine administration, which suggests that it has antidepressant effects. This is in line with previous reports in mice (12,13). Considering the structural commonality of l-theanine to l-glutamate, the primary site of action is likely to be the glutamatergic pathway which is a therapeutic target for depression (39,40). Meta-analyses have reported that ketamine, a non-competitive glutamate receptor antagonist, is effective in treating depressive disorders (41,42). l-Theanine has a lower affinity for glutamate receptors than does L-glutamate itself (8). We showed that l-theanine could exert a partially agonistic effect on glutamate receptors (13) and regulate the concentration of glutamate and glutamine in the brain (24). Although detailed mechanisms are unknown, it is possible that, similar to a low dose of ketamine (43), l-theanine might normalise impaired glutamatergic transmission in MDD.

We found a tendency for reduction in anxiety-state scores and a significant reduction in anxiety-trait scores after l-theanine administration. This may suggest its anxiolytic effects in our patients with MDD, which is corroborated by previous studies in mice and humans (14,16,23). This effect might be attributable again to the action of l-theanine on glutamate receptors, because modulators of the...
receptors have shown their anxiolytic effects (44). Increased level of central nervous system inhibitory neurotransmitters, such as glycine (45) and α-amino- butyric acid (46), following theanine administration may also contribute to the anxiolytic effects. Further, we found a significant improvement of sleep disturbance after L-theanine administration in our patients with MDD. In line with this, L-theanine has been suggested to help ameliorate sleep quality in patients with MDD as in attention deficit hyperactivity disorder (47) and schizophrenia (24).

We found enhanced cognitive functions after L-theanine administration in line with previous reports in rats, mice, and humans (9,10,12,15,21,22). Although one recent double-blind randomised controlled trial reported that L-theanine had no beneficial effect on cognition in healthy coffee drinkers (48), the dose (50 mg) was substantially lower than ours (250 mg). Further, it was single, but not chronic L-theanine administration. In the Stroop test, response latency and error rates were significantly reduced in patients with MDD. The Stroop task is relevant to prefrontal cortical activity and other conflict-processing functional areas in the brain (49). In the BACS, verbal memory and executive function scores of the patients significantly improved in this study. L-theanine may improve verbal memory and executive function by modulating the involved cortical areas through its putative α-wave activity related to attention and memory in healthy subjects in electroencephalogram studies (17–19).

As discussed in Godsil et al. (50), the hippocampus-prefrontal pathway might be related with the treatment response to L-theanine administration. In the hippocampus and prefrontal cortex, glutamatergic signalling is an essential regulator underlying synaptic plasticity. Disrupted function in this system can constitute the pathology of MDD and present a novel therapeutic target or research of antidepressant (51). Considering that stress-related impairment of hippocampal synaptic plasticity was recovered (9), and that the augmentation of hippocampal synaptic plasticity was observed (10) in L-theanine-administered rats, the antidepressant and cognition-enhancing effects might also be related to the effect on synaptic plasticity.

In laboratory data, HDL cholesterol, alternatively called as ‘good’ cholesterol, was significantly reduced after L-theanine administration. This result is opposite to a report that the levels of HDL cholesterol increased in the theanine-supplemented group in hepatoma-bearing rats (52). Although the mechanisms underlying our result were elusive, there were no subjects who newly showed the value below the lower limit of reference range (40 mg/dl) at 8 weeks.

There are several limitations in our study. First, we cannot exclude the influence of the placebo effect on our results. Placebo-controlled clinical trials are required to confirm the therapeutic effect of L-theanine as an adjunct therapy in the treatment of MDD. Second, although a significant reduction in depressive symptoms were seen after L-theanine administration, the mean HAMD-21 score at baseline was 12.5 points, indicating that the patients presented relatively mild forms of MDD, which might have obscured the possible antidepressant effect.

In conclusion, reduced depressive symptoms, anxiety, sleep disturbance, and enhanced cognitive functions were found in patients with MDD after chronic (8-week) L-theanine (250 mg/day) administration. We also found high tolerability of L-theanine. These results suggest that L-theanine could be a useful natural compound in the treatment of MDD.

Acknowledgements

The authors thank Ikki Ishida, Moeko Hiraishi, Anna Nagashima, and Dr. Junko Matsuo for their assistance in the recruitment of subjects. Authors’ Contributions: S.H., M.O. and H.K. designed the study and H.K. supervised the results. C.W. was involved in supporting the intellectual content. T.N. helped recruitment of subjects from the outpatient clinic. T.O. provided important knowledge about L-theanine and critical comments to the study. H.O. carried out high-performance liquid chromatography analysis. S.H. evaluated clinical assessments, executed statistical analyses, and wrote the manuscript, which was revised and approved by all authors.

Financial Support

This study was supported by an Intramural Research Grant (M.O. and H.K., grant number 24–11, 27–1) for Neurological and Psychiatric Disorders of National Center of Neurology and Psychiatry, and an unrestricted research grant provided by the Taiyo Kagaku Co. Ltd.

Conflicts of Interest

H.O. and T.O. are employees of Taiyo Kagaku Co. Ltd., which provided L-theanine tablets used in the present study, and various food products.

Ethical Standards

The authors assert that all procedures contributing to this work comply with the ethical standards of the ethics committee of National Center of Neurology and Psychiatry and with the Helsinki Declaration of 1975, as revised in 2008.
References


42. Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol 2014;4:75–99.


